Open AccessDOTATATE Uptake in an Axillary Lymph Node After COVID-19 Vaccination
Author(s) -
James M. Brophy,
Gregory Henkle,
Eric M. Rohren
Publication year - 2021
Publication title -
clinical nuclear medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.637
H-Index - 57
eISSN - 1536-0229
pISSN - 0363-9762
DOI - 10.1097/rlu.0000000000003847
Subject(s) - medicine , vaccination , covid-19 , lymph node , axillary lymph nodes , lymph , adjuvant , radiology , surgery , pathology , breast cancer , cancer , disease , infectious disease (medical specialty)
A 58-year-old man underwent DOTATATE PET/CT scan for follow-up of pulmonary neuroendocrine tumor after resection and adjuvant chemotherapy. On screening paperwork, the patient indicated having received the Johnson & Johnson/Janssen COVID-19 vaccine (Janssen Biotech, Inc) 1 day previously, administered in the right deltoid muscle. Reactive changes in regional lymph nodes is a known response for all 3 currently Food and Drug Administration-approved COVID-19 vaccines. Recent published data have demonstrated FDG PET-avid axillary lymphadenopathy subsequent to COVID-19 vaccination, and included here is a report of DOTATATE PET-avid axillary lymph node after injection of the Johnson & Johnson COVID-19 vaccine.